Pharmaceuticals
Samsung BioLogics and UCB Sign Third Drug Manufacturing Deal
INCHEON, South Korea, July 31, 2019 /PRNewswire/ -- Samsung BioLogics (SBL) and UCB have agreed to an additional drug substance manufacturing deal under which SBL will also produce UCB's anti-tau candidate to treat progressive supranuclear palsy, pending regulatory approvals. UCB's anti-tau candi...
2019-07-31 19:00
1650
GC Pharma Reports Q2 2019 Results
YONGIN, South Korea, July 30, 2019 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months endedJune 30, 2019. Key Figures Q2 2019(1) Growth(1) Total revenues KRW 35...
2019-07-30 22:31
7868
Scala and FUTURAMEDIA Drive French Pharmacy Sales with Digital Signage
Point of sale and street-facing Scala-driven digital signage screens increase product sales by up to 80% in thousands of pharmacies acrossFrance SITTARD, The Netherlands, July 30, 2019 /PRNewswire/ -- Scala, part of the STRATACACHE family of digital media/marketing technology companies, has been ...
2019-07-30 17:00
1355
HKSH Medical Group Brings Precision Radiation Medicine to Cancer Patients in Asia With Elekta Unity MR-Linac
HONG KONG, July 30, 2019 /PRNewswire/ -- Elekta Unity, a transformative magnetic resonance radiation therapy (MR/RT) system that enables personalized precision radiation therapy, is in clinical use at HKSH Cancer Centre. The milestone marks the first clinical use of Elekta Unity inAsia. HKSH rec...
2019-07-30 13:47
5973
Internationally Renowned Radiation Oncologist, Prof. Dr. Dattatreyudu Nori Appointed as International Director, Apollo Cancer Centres, Apollo Hospitals Group
NEW DELHI, July 29, 2019 /PRNewswire/ -- Apollo Hospitals have appointed world renowned Radiation Oncologist, Prof. Dr. Dattatreyudu Nori, as International Director – Apollo Cancer Centres, Apollo Hospitals Group. Beginning this month, Dr. Nori will be available for consultations 10 times at Apol...
2019-07-29 22:17
3452
Submission and acceptance of application for the production of new drug for Yisaipu(R)aqueous injection solution
SHANGHAI, July 29, 2019 /PRNewswire/ -- 3SBio Inc. (01530.HK), a leading biopharmaceutical company in the PRC, announces today that an application for the production of new drug has been submitted to the National Medical Products Administration for Yisaipu® pre-filled aqueous injection solution (...
2019-07-29 21:42
5392
Alvotech and Cipla Gulf Enter Into a Partnership for the Commercialization of Key Biosimilar in Select Emerging Markets
REYKJAVIK, Iceland and MUMBAI, India, July 29, 2019 /PRNewswire/ -- Biopharmaceutical company Alvotech and Cipla Gulf FZ LLC ("Cipla Gulf"), a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087) (NSE: CIPLA EQ; hereafter referred to as "Cipla"), today ...
2019-07-29 12:00
5482
NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation
LUND, Sweden, July 28, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company's candidate drug NeuroSTAT, in development for treatment of moderate to severe traumatic brain injury, TBI, has received Fast Track designation from the ...
2019-07-28 21:47
5538
China Biologic Products to Report Second Quarter 2019 Financial Results
BEIJING, July 26, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its second quarter 2019 financial resu...
2019-07-27 04:30
10323
Sanofi Announces Participation in 2nd China International Import Expo
SHANGHAI, July 26, 2019 /PRNewswire/ -- At today's Matchmaking Meeting for Medical Devices and Medical Health Care Exhibitors and Buyers of the 2nd China International Import Expo (CIIE), Sanofi officially announced that it would participate in the 2nd CIIE held in the National Convention and Exh...
2019-07-26 21:50
3668
Novartis, Mundipharma ink partnership to enhance access to three Asian countries to established medicine brands for glaucoma and external eye diseases
* Novartis and Mundipharma have signed an agreement for Mundipharma to market, sell and distribute Novartis medicines in the general ophthalmology disease area, including medicines for glaucoma and external eye diseases in Taiwan. This follows recent agreements for the Philippines and Thailand. ...
2019-07-26 12:25
2550
Penta and CROMSOURCE Announce Their Partnership to Improve Paediatric Drug Development
VERONA, Italy, July 25, 2019 /PRNewswire/ -- Penta ID Innovation, a recently established SMO stemmed from the Penta Global Paediatric Research Network, and CROMSOURCE, an international contract research organization (CRO) providing a comprehensive portfolio of services to the pharmaceutical, biot...
2019-07-25 19:00
3231
First Patient Dosed in Sintilimab and Anti-VEGF Monoclonal Antibody IBI305 with Chemotherapy in Patients with EGFR-mutant Non-squamous NSCLC who have Progressed from Prior EGFR-TKI Treatment
SUZHOU, China, July 25, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality innovative medicines for the treatment of oncology, autoimmune and other major diseases, today announ...
2019-07-25 08:16
3112
NanoCellect Biomedical Expands Distribution to Australia and New Zealand
Company enters exclusive agreement with Millennium Science Pty Ltd SAN DIEGO, California, July 24, 2019 /PRNewswire/ -- NanoCellect Biomedical Inc., a leader in the development and manufacture of microfluidic cell sorting solutions for cell-based assays, today announced an exclusive agreement wit...
2019-07-24 21:57
1731
111 Signs Strategic Cooperation with Harbin Pharmaceutical Group
SHANGHAI, July 24, 2019 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading integrated online and offline healthcare platform, today announced the signing of a strategic cooperation agreement with Harbin Pharmaceutical Group Holding Co., Ltd. (HPGC, SHSE: 600664), which has...
2019-07-24 20:00
8190
SINOMED® Concludes Enrollment of the PIONEER III Randomized, Pivotal Study of the BuMA Supreme® Coronary Drug-Eluting Stent
TIANJIN, China, July 23, 2019 /PRNewswire/ -- In a significant milestone toward obtaining key regulatory approvals for the BuMA Supreme Drug-Eluting Stent (DES) System, SINOMED has completed enrollment in the PIONEER III randomized, controlled clinical trial. The PIONEER III trial is designed to...
2019-07-23 15:00
2852
Huge CPhI & P-MEC China a direct result of surging manufacturing
SHANGHAI, July 23, 2019 /PRNewswire/ -- CPhI and P-MEC China – organized by China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE), Informa Markets, andShanghai Sinoexpo Informa Markets – saw record numbers of attendees as the pharma market inChina continues to gr...
2019-07-23 13:18
2272
WuXi STA Shanghai & Changzhou Facilities Pass U.S. FDA Inspections
SHANGHAI, July 23, 2019 /PRNewswire/ -- STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announces that its Analytical Service Unit (ASU) inShanghai and active pharmaceutical ingredient (API) process R&D and manufacturing facility in Changzhou, have successfully passed two...
2019-07-23 12:48
3334
CStone receives approval in China to initiate ivosidenib Phase I bridging registrational study for the treatment of IDH1 mutant relapsed or refractory AML
SUZHOU, China, July 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) announced today that it has received approval from China National Medical Products Administration (NMPA) to initiate a Phase I bridging registrational study of ivosidenib (TIBSOVO) for the treatment of rela...
2019-07-22 12:17
7110
Ascentage Pharma to Initiate Phase Ib Study of HQP1351 in Tyrosine Kinase Inhibitors -resistant Chronic Myeloid Leukemia Patients in the US
SUZHOU, China and ROCKVILLE, Md., July 22, 2019 /PRNewswire/ -- Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced that the company was notified by the U.S. Food ...
2019-07-22 07:00
2976
Week's Top Stories
Most Reposted
Multiple achievements made in China-Hungary BRI conference
[Picked up by 319 media titles]
2024-05-03 06:59
Shanghai Jiao Tong University Offers Free Online Courses for International Learners, Joint Programs with Tmall of Alibaba and Dow Gain High Popularity
[Picked up by 316 media titles]
2024-05-07 08:00
Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 289 media titles]
2024-05-03 06:25TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 262 media titles]
2024-05-02 01:21
China-Serbia forum highlights community with shared future for mankind
[Picked up by 245 media titles]
2024-05-01 11:39
Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
13160
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
9127
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
8645
